A Phase II trial to assess the efficacy and safety of pasireotide s.c. alone or in combination with cabergoline in patients with Cushing's disease
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Cabergoline (Primary) ; Pasireotide (Primary)
- Indications Pituitary ACTH hypersecretion
- Focus Therapeutic Use
- Acronyms CAPACITY
- Sponsors Novartis; Novartis Pharmaceuticals
- 28 Aug 2020 Status changed from completed to discontinued.
- 21 May 2020 Status changed from discontinued to completed.
- 09 Mar 2020 Status changed from active, no longer recruiting to discontinued.